Long-Acting HIV Therapies Lift 7MM Market to $30.6 Billion as Cabenuva, ISL/LEN Post New Data
Updated
Updated · POZ · Aug 14
Long-Acting HIV Therapies Lift 7MM Market to $30.6 Billion as Cabenuva, ISL/LEN Post New Data
3 articles · Updated · POZ · Aug 14
Summary
$30.6 billion is GlobalData’s 2033 forecast for the HIV market in seven major markets, up from $26.4 billion in 2023, with long-acting therapies seen as a main growth driver.
At AIDS 2026, ViiV’s Cabenuva showed every-other-month injections were superior to daily oral antiretroviral therapy for virologic suppression in adolescents living with HIV.
Phase III results also showed Gilead and Merck’s once-weekly oral islatravir/lenacapavir was non-inferior to daily regimens in maintaining viral suppression after patients switched from standard care.
GlobalData said competition is shifting from efficacy alone toward adherence, pill-burden reduction and convenience, as patients and clinicians seek more discreet treatment options.
Broader uptake still faces hurdles including affordability, reimbursement and the extra manufacturing, storage and administration demands of injectable therapies.